{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:48:51Z","timestamp":1791568131058,"version":"4.3.4"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"am","delay-in-days":267,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023621","name":"University of Illinois College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["K23EY028230"],"award-info":[{"award-number":["K23EY028230"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30EY001792"],"award-info":[{"award-number":["P30EY001792"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtos.2025.06.004","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T20:08:00Z","timestamp":1750277280000},"page":"104-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Attribution of causality in Stevens-Johnson syndrome\/toxic epidermal necrolysis"],"prefix":"10.1016","volume":"38","author":[{"given":"Asha","family":"Parvathaneni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliya","family":"Benchetrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandong","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tav\u00e9","family":"Van Zyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajirah N.","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7463-1599","authenticated-orcid":false,"given":"James","family":"Chodosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2025.06.004_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necsyndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12886-017-0464-9","article-title":"Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study","volume":"17","author":"Chow","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jtos.2025.06.004_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ophtha.2010.06.035","article-title":"Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis","volume":"118","author":"Lopez-Garcia","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2025.06.004_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.bcr.0000194268.01514.f8","article-title":"Long-term follow-up of patients treated for toxic epidermal necrolysis","volume":"27","author":"Oplatek","year":"2006","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.jtos.2025.06.004_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/ICU.0000000000000312","article-title":"Ocular manifestations of Stevens-Johnson syndrome and their management","volume":"27","author":"Saeed","year":"2016","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jtos.2025.06.004_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.13562","article-title":"EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity","volume":"74","author":"Brockow","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jtos.2025.06.004_bib7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.autrev.2008.06.004","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Borchers","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtos.2025.06.004_bib8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/BCR.0b013e3181848bb1","article-title":"Toxic epidermal necrolysis clinical guidelines","volume":"29","author":"Endorf","year":"2008","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.jtos.2025.06.004_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jtos.2015.10.002","article-title":"Stevens-Johnson syndrome\/toxic epidermal Necrolysis--A comprehensive review and guide to therapy. I. Systemic disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.06.004_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib11","first-page":"6","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4065\/mcp.2009.0379","article-title":"Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo clinic","volume":"85","author":"Wetter","year":"2010","journal-title":"Mayo Clinic proceedings Mayo Clinic"},{"key":"10.1016\/j.jtos.2025.06.004_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cmpb.2013.07.004","article-title":"Developing a data mining approach to investigate association between physician prescription and patient outcome - a study on re-hospitalization in Stevens-Johnson syndrome","volume":"112","author":"Ou-Yang","year":"2013","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.jtos.2025.06.004_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1542\/peds.2010-3322","article-title":"Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children","volume":"128","author":"Finkelstein","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtos.2025.06.004_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.912478","article-title":"Susceptibility genes and HLA for cold medicine-related SJS\/TEN with SOC","volume":"13","author":"Ueta","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.jtos.2025.06.004_bib17","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1097\/ICO.0000000000000646","article-title":"Incidence of Stevens-Johnson syndrome and chemical burns to the eye","volume":"34","author":"White","year":"2015","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.06.004_bib18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jtos.2025.06.004_bib21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jtos.2025.06.004_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2332\/allergolint.10-RAI-0261","article-title":"Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"59","author":"Chung","year":"2010","journal-title":"Allergol Int"},{"key":"10.1016\/j.jtos.2025.06.004_bib23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00130832-200208000-00003","article-title":"Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept","volume":"2","author":"Pichler","year":"2002","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000441280","article-title":"Drug hypersensitivity: how drugs stimulate T cells via pharmacological interaction with immune receptors","volume":"168","author":"Pichler","year":"2015","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1272\/jnms.83.216","article-title":"A review of the pathogenesis of toxic epidermal necrolysis","volume":"83","author":"Kinoshita","year":"2016","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.jtos.2025.06.004_bib27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin pharmacol therapeutics"},{"key":"10.1016\/j.jtos.2025.06.004_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/000992289103000107","article-title":"Mycoplasma pneumoniae infections and Stevens-Johnson syndrome. Report of eight cases and review of the literature","volume":"30","author":"Levy","year":"1991","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.jtos.2025.06.004_bib29","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/pde.12482","article-title":"Mycoplasma pneumonia--associated mucocutaneous disease in children: dilemmas in classification","volume":"31","author":"Prindaville","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib30","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/COC.0b013e31825d5835","article-title":"Erythema multiforme, stevens johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review","volume":"37","author":"Vern-Gross","year":"2014","journal-title":"American journal of clinical oncology"},{"key":"10.1016\/j.jtos.2025.06.004_bib31","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2025.06.004_bib32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.burns.2016.01.014","article-title":"A decade of burn unit experience with stevens-johnson syndrome\/toxic epidermal necrolysis: clinical pathological diagnosis and risk factor awareness","volume":"42","author":"Lim","year":"2016","journal-title":"Burns"},{"key":"10.1016\/j.jtos.2025.06.004_bib33","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jamadermatol.2021.1136","article-title":"Long-term physical and psychological outcomes of stevens-johnson syndrome\/toxic epidermal necrolysis","volume":"157","author":"Hoffman","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib35","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.burns.2024.07.006","article-title":"Lamotrigine emerging as a driver of Stevens-Johnson syndrome and toxic epidermal necrolysis: an 8-Year retrospective study","volume":"50","author":"Glahn","year":"2024","journal-title":"Burns"},{"key":"10.1016\/j.jtos.2025.06.004_bib36","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00228-019-02670-9","article-title":"Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement","volume":"75","author":"Goldman","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtos.2025.06.004_bib37","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.jaad.2018.10.058","article-title":"Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and patients' characteristics","volume":"80","author":"Chaby","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jtos.2025.06.004_bib39","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/archderm.1987.01660330077013","article-title":"The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome)","volume":"123","author":"Guillaume","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171470","article-title":"Imputation of adverse drug reactions: causality assessment in hospitals","volume":"12","author":"Varallo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jtos.2025.06.004_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1574886316666210611160123","article-title":"Agreement among different scales for causality assessment in drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"17","author":"Sivagourounadin","year":"2022","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.jtos.2025.06.004_bib42","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/pds.5399","article-title":"Biases associated with epidermal necrolysis reporting in pharmacovigilance: an exploratory analysis using world health organization VigiBase","volume":"31","author":"Bettuzzi","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtos.2025.06.004_bib43","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamadermatol.2023.1693","article-title":"Assessment of need for improved identification of a culprit drug in stevens-johnson syndrome\/toxic epidermal necrolysis","volume":"159","author":"Li","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/ACI.0000000000000546","article-title":"Making a diagnosis in severe cutaneous drug hypersensitivity reactions","volume":"19","author":"Ardern-Jones","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib46","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.2174\/1381612825666191107104126","article-title":"Role of in vivo and in vitro tests in the diagnosis of Severe Cutaneous Adverse Reactions (SCAR) to drug","volume":"25","author":"Bergmann","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jtos.2025.06.004_bib47","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12016-022-08924-2","article-title":"The role of patch testing in evaluating delayed hypersensitivity reactions to medications","volume":"62","author":"Woodruff","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib48","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.anai.2023.01.006","article-title":"Drug patch testing in Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review","volume":"130","author":"Novack","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.anai.2023.02.007","article-title":"Drug patch testing for severe cutaneous adverse reactions: not in the United States?","volume":"130","author":"Whitley","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2222.2011.03701.x","article-title":"In vitro diagnosis of T cell-mediated drug allergy","volume":"41","author":"Porebski","year":"2011","journal-title":"Clin Exp Allergy : j Br Soc Allergy and Clin Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib51","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","article-title":"The lymphocyte transformation test in the diagnosis of drug hypersensitivity","volume":"59","author":"Pichler","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jtos.2025.06.004_bib52","first-page":"293","article-title":"Multiple drug hypersensitivity--proof of multiple drug hypersensitivity by patch and lymphocyte transformation tests","volume":"15","author":"Gex-Collet","year":"2005","journal-title":"J investig allergol clin immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000448284","article-title":"Evaluation of lymphocyte transformation test results in patients with delayed hypersensitivity reactions following the use of anticonvulsant drugs","volume":"170","author":"Karami","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib54","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1398-9995.2007.01553.x","article-title":"Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption","volume":"62","author":"Kano","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jtos.2025.06.004_bib55","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/all.14062","article-title":"Assessment of drug causality in stevens-johnson syndrome\/toxic epidermal necrolysis: concordance between lymphocyte transformation test and ALDEN","volume":"75","author":"Bellon","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jtos.2025.06.004_bib56","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2222.2011.03875.x","article-title":"Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"42","author":"Tang","year":"2012","journal-title":"Clin Exp Allergy : j Br Soc Allergy and Clin Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib57","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1034\/j.1398-9995.2001.000115.x","article-title":"In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions","volume":"56","author":"Luque","year":"2001","journal-title":"Allergy"},{"key":"10.1016\/j.jtos.2025.06.004_bib58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2222.1997.tb00690.x","article-title":"The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity","volume":"27","author":"Nyfeler","year":"1997","journal-title":"Clin Exp Allergy : j Br Soc Allergy and Clin Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib59","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/all.12886","article-title":"In vitro tests for drug hypersensitivity reactions: an ENDA\/EAACI drug allergy interest group position paper","volume":"71","author":"Mayorga","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jtos.2025.06.004_bib60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaci.2018.09.022","article-title":"Controversies in drug allergy: in vitro testing","volume":"143","author":"Mayorga","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000358491","article-title":"Enhancement of drug-specific lymphocyte proliferation using CD25(hi)-depleted CD3(+) effector cells","volume":"163","author":"Srinoulprasert","year":"2014","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000233856","article-title":"Lymphocyte transformation test in drug-induced toxic epidermal necrolysis","volume":"78","author":"Roujeau","year":"1985","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081737","article-title":"In vitro assays in severe cutaneous adverse drug reactions: are they still research tools or diagnostic tests already?","volume":"18","author":"Porebski","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtos.2025.06.004_bib64","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.intimp.2018.08.010","article-title":"Evaluation of a lymphocyte transformation test and cytokine detection assay to identify phenytoin and carbamazepine provoked DRESS or SJS\/TEN in epilepsy patients","volume":"63","author":"Kumkamthornkul","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jtos.2025.06.004_bib65","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1398-9995.2009.01985.x","article-title":"Drug-specific in vitro release of IL-2, IL-5, IL-13 and IFN-gamma in patients with delayed-type drug hypersensitivity","volume":"64","author":"Lochmatter","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jtos.2025.06.004_bib66","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjd.12109","article-title":"In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions","volume":"168","author":"Polak","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib67","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/cea.12145","article-title":"In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test","volume":"43","author":"Porebski","year":"2013","journal-title":"Clin Exp Allergy : j Br Soc Allergy and Clin Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib68","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1398-9995.2009.02143.x","article-title":"In vitro detection and characterization of drug hypersensitivity using flow cytometry","volume":"65","author":"Martin","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jtos.2025.06.004_bib69","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jid.2020.11.027","article-title":"Granulysin-based lymphocyte activation test for evaluating drug causality in antiepileptics-induced severe cutaneous adverse reactions","volume":"141","author":"Chu","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib70","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/bjd.14701","article-title":"In vitro test to confirm diagnosis of allopurinol-induced severe cutaneous adverse reactions","volume":"175","author":"Klaewsongkram","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib71","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2009.02180.x","article-title":"In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases","volume":"65","author":"Zawodniak","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jtos.2025.06.004_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.05.002","article-title":"Galectin-7 as a potential biomarker of stevens-johnson syndrome\/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells","volume":"7","author":"Hama","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jtos.2025.06.004_bib73","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa","year":"2020","journal-title":"F1000Res"},{"key":"10.1016\/j.jtos.2025.06.004_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.01.006","article-title":"RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"8","author":"Hasegawa","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jtos.2025.06.004_bib75","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.anai.2014.05.006","article-title":"Chemokine expression in diverse nonimmediate drug hypersensitivity reactions: focus on thymus activation-regulated chemokine, cutaneous T-cell-attracting chemokine, and interleukin-10","volume":"113","author":"Wang","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jtos.2025.06.004_bib76","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13601-018-0199-6","article-title":"Diverse expression of TNF-alpha and CCL27 in serum and blister of stevens-johnson syndrome\/toxic epidermal necrolysis","volume":"8","author":"Wang","year":"2018","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jtos.2025.06.004_bib77","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.36740\/WLek202009202","article-title":"Examining the role of the nitric oxid system as the essential pathogenetic link in Stevens-Johnson syndrome","volume":"73","author":"Ivanyushko-Nazarko","year":"2020","journal-title":"Wiadomosci lekarskie"},{"key":"10.1016\/j.jtos.2025.06.004_bib78","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/jdv.16339","article-title":"Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN)","volume":"34","author":"Kuijper","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jtos.2025.06.004_bib79","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jtos.2025.06.004_bib80","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"HLA-B\u22171502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jtos.2025.06.004_bib81","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1111\/epi.17726","article-title":"Impact on carbamazepine usage and cutaneous adverse reactions before and after the reimbursement of HLA-B\u22171502 genotyping in Taiwan, 2000-2017: a nationwide longitudinal study","volume":"64","author":"Chang","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.jtos.2025.06.004_bib82","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A\u22173101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2025.06.004_bib83","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/all.13821","article-title":"HLA-B\u221757:01 confers genetic susceptibility to carbamazepine-induced SJS\/TEN in Europeans","volume":"74","author":"Mockenhaupt","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jtos.2025.06.004_bib84","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/epi.12564","article-title":"Recommendations for HLA-B\u221715:02 and HLA-A\u221731:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions","volume":"55","author":"Amstutz","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.jtos.2025.06.004_bib85","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamadermatol.2018.5336","article-title":"Screening HLA to prevent severe drug Reactions-A devil's advocate perspective","volume":"155","author":"Divito","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib86","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(00)02826-9","article-title":"Epidemiological assessment of drug-induced disease","volume":"356","author":"Kaufman","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jtos.2025.06.004_bib87","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B\u22175801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.jtos.2025.06.004_bib88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/tpj.2011.41","article-title":"A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"13","author":"Tohkin","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jtos.2025.06.004_bib89","first-page":"526","article-title":"Chronic ocular sequelae in Stevens-Johnson syndrome: a genetic association study","volume":"28","author":"Sangwan","year":"2022","journal-title":"Mol Vis"},{"key":"10.1016\/j.jtos.2025.06.004_bib90","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib91","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jaad.2014.06.026","article-title":"Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review","volume":"72","author":"Canavan","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib92","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0190-9622(96)90732-X","article-title":"Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von hebra)","volume":"35","author":"Tay","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib93","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archdermatol.2012.681","article-title":"Stevens-johnson syndrome without skin lesions (fuchs syndrome): a literature review of adult cases with mycoplasma cause","volume":"148","author":"Li","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib94","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jaad.2021.04.066","article-title":"Mycoplasma-induced stevens-johnson syndrome\/toxic epidermal necrolysis: case-control analysis of a cohort managed in a specialized center","volume":"86","author":"Liew","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib95","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ced.14404","article-title":"Reactive infectious mucocutaneous eruption: mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions","volume":"46","author":"Ramien","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib96","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/pde.13921","article-title":"Two pediatric cases of influenza B-induced rash and mucositis: Stevens-johnson syndrome or expansion of the mycoplasma pneumoniae-induced rash with mucositis (MIRM) spectrum?","volume":"36","author":"Goyal","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib97","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaad.2023.03.027","article-title":"Recurrent reactive infectious mucocutaneous eruption: a retrospective cohort study","volume":"89","author":"Pan","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib98","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/pde.15407","article-title":"COVID-19 associated severe mucocutaneous blistering eruptions: a case series","volume":"40","author":"Miller","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib99","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jaad.2021.12.037","article-title":"More than Mycoplasma-induced rash and mucositis: the potential role of Mycoplasma pneumoniae in stevens-johnson syndrome\/toxic epidermal necrolysis","volume":"86","author":"Heymann","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib100","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1542\/peds.2015-0278","article-title":"Outbreak of mycoplasma pneumoniae-Associated Stevens-Johnson syndrome","volume":"136","author":"Olson","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtos.2025.06.004_bib101","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jtos.2022.03.004","article-title":"Acute ophthalmic manifestations in mycoplasma induced rash and mucositis","volume":"24","author":"Rashad","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.06.004_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaapos.2021.06.003","article-title":"Ophthalmic findings of Mycoplasma-induced rash and mucositis (MIRM) distinct from Stevens-Johnson syndrome","volume":"25","author":"Khalili","year":"2021","journal-title":"J AAPOS"},{"key":"10.1016\/j.jtos.2025.06.004_bib103","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/ICO.0000000000001985","article-title":"Ophthalmic manifestations of mycoplasma-induced rash and mucositis","volume":"38","author":"Shah","year":"2019","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.06.004_bib104","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/0128071-200809060-00008","article-title":"Mycoplasma pneumoniae-associated mucositis with minimal skin manifestations","volume":"9","author":"Figueira-Coelho","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jtos.2025.06.004_bib105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fmicb.2016.00039","article-title":"Antibody response to Mycoplasma pneumoniae: protection of host and influence on outbreaks?","volume":"7","author":"Dumke","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jtos.2025.06.004_bib106","article-title":"Mycoplasma pneumoniae-associated mucositis: a recently described entity","volume":"5","author":"Zao","year":"2018","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.jtos.2025.06.004_bib107","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/jdv.12392","article-title":"Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature","volume":"29","author":"Vujic","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jtos.2025.06.004_bib108","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF02013977","article-title":"Stevens-Johnson syndrome with isolation of Mycoplasma pneumoniae from skin lesions","volume":"5","author":"Meseguer","year":"1986","journal-title":"Eur J Clin Microbiol"},{"key":"10.1016\/j.jtos.2025.06.004_bib109","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0022-3476(87)80200-7","article-title":"Stevens-Johnson syndrome and Mycoplasma pneumoniae: evidence for cutaneous infection","volume":"111","author":"Stutman","year":"1987","journal-title":"J Pediatr"},{"key":"10.1016\/j.jtos.2025.06.004_bib110","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaip.2018.07.033","article-title":"Mycoplasma-induced toxic epidermal necrolysis with severe mucositis","volume":"7","author":"Liu","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jtos.2025.06.004_bib111","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02113442","article-title":"Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection","volume":"14","author":"Fournier","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jtos.2025.06.004_bib112","doi-asserted-by":"crossref","first-page":"e1048","DOI":"10.7205\/MILMED-D-13-00139","article-title":"Toxic epidermal necrolysis from suspected Mycoplasma pneumoniae infection","volume":"178","author":"McDermott","year":"2013","journal-title":"Mil Med"},{"key":"10.1016\/j.jtos.2025.06.004_bib113","volume":"2019","author":"Sah","year":"2019"},{"key":"10.1016\/j.jtos.2025.06.004_bib114","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1503\/cmaj.151017","article-title":"Mycoplasma pneumoniae-associated mucositis","volume":"188","author":"Alcantara-Reifs","year":"2016","journal-title":"CMAJ (Can Med Assoc J) : Can Med Assoc j"},{"key":"10.1016\/j.jtos.2025.06.004_bib115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2340\/00015555-2180","article-title":"Synergistic effects of Mycoplasma pneumoniae infection and drug reaction on the development of atypical Stevens-Johnson Syndrome in adults","volume":"96","author":"Kurata","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jtos.2025.06.004_bib116","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jdcr.2017.03.005","article-title":"Multiple drug sensitization syndrome: a distinct phenotype associated with unrecognized Mycoplasma pneumonia infection","volume":"3","author":"Aoyama","year":"2017","journal-title":"JAAD Case Rep"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425000825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425000825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:59:55Z","timestamp":1764755995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012425000825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":116,"alternative-id":["S1542012425000825"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2025.06.004","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attribution of causality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2025.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}